Blueprint Medicines (BPMC) Set to Announce Quarterly Earnings on Thursday

Blueprint Medicines (NASDAQ:BPMC) is set to issue its quarterly earnings data before the market opens on Thursday, April 25th. Analysts expect the company to announce earnings of ($1.65) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share for the quarter, beating the consensus estimate of ($2.04) by $0.22. The business had revenue of $71.96 million during the quarter, compared to analyst estimates of $67.34 million. Blueprint Medicines had a negative return on equity of 191.56% and a negative net margin of 203.30%. The company’s revenue was up 85.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($2.65) earnings per share. On average, analysts expect Blueprint Medicines to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Blueprint Medicines Price Performance

NASDAQ:BPMC opened at $92.29 on Wednesday. The company has a quick ratio of 3.66, a current ratio of 3.76 and a debt-to-equity ratio of 1.60. The business’s 50-day moving average price is $90.36 and its 200 day moving average price is $78.32. Blueprint Medicines has a 52-week low of $43.89 and a 52-week high of $101.00. The firm has a market cap of $5.65 billion, a P/E ratio of -11.04 and a beta of 0.63.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $114.00 price objective on shares of Blueprint Medicines in a research note on Wednesday, April 10th. Stifel Nicolaus lifted their price target on shares of Blueprint Medicines from $95.00 to $97.00 and gave the stock a “buy” rating in a research report on Tuesday, January 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $97.00 price target on shares of Blueprint Medicines in a report on Monday, February 26th. Wedbush reissued an “outperform” rating and set a $97.00 price objective on shares of Blueprint Medicines in a research note on Monday, February 5th. Finally, Citigroup lifted their target price on Blueprint Medicines from $54.00 to $65.00 and gave the stock a “sell” rating in a report on Friday, February 16th. Four analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $85.43.

Insider Activity at Blueprint Medicines

In related news, CFO Michael Landsittel sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $95.00, for a total transaction of $475,000.00. Following the completion of the sale, the chief financial officer now directly owns 47,286 shares in the company, valued at $4,492,170. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CEO Kate Haviland sold 12,464 shares of the stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $90.69, for a total transaction of $1,130,360.16. Following the completion of the sale, the chief executive officer now directly owns 153,177 shares in the company, valued at $13,891,622.13. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Michael Landsittel sold 5,000 shares of the business’s stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $95.00, for a total value of $475,000.00. Following the completion of the transaction, the chief financial officer now owns 47,286 shares in the company, valued at approximately $4,492,170. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 117,289 shares of company stock valued at $10,361,913. Company insiders own 3.88% of the company’s stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.